UK Rare Cancers Act 2026: trial access, privacy rules

Parliament has now made the Rare Cancers Act 2026 law (Royal Assent on 5 March 2026), with the Act starting on 5 May 2026. We’ll walk through what changes for patients, researchers and schools, and what stays protected. House of Commons Votes and Proceedings records the Royal Assent, and the Act’s text sets the two‑month commencement. (commonsbusiness.parliament.uk)

First, who counts as “rare”? In UK law under this Act, a rare cancer is defined against the population: not more than 1 in 2,000 people are affected. That focuses support where patient numbers are small but need is high. The figure also matches the European threshold of 5 in 10,000. (commonslibrary.parliament.uk)

Finding people for trials has been a stumbling block. Under the Act, NHS England can use information it already holds to help identify and contact people who might be eligible for relevant clinical trials in rare cancers, including trials based outside the UK. That contact is an invitation to learn more, not automatic enrolment. (hansard.parliament.uk)

Privacy protections stay in force. Parliament’s debate and the final wording make clear that any information processing under this gateway must not contravene the Data Protection Act 2018. In other words, your rights continue to apply and the usual tests-lawfulness, fairness, necessity and minimisation-still govern what can be done. (hansard.parliament.uk)

To keep research moving, a National Specialty Lead for Rare Cancers must be appointed. Their brief is to advise on study design and planning, and to bring together the people who need to work on these trials-from NHS teams to universities and charities-so projects are better set up to succeed. (bills.parliament.uk)

So what is an “orphan medicinal product”? The MHRA explains that an orphan designation can apply when a medicine targets a condition affecting not more than 5 in 10,000 people in Great Britain (the same as 1 in 2,000), or when expected sales would not cover development costs; and if a treatment already exists, the new one must show significant benefit. (gov.uk)

Why companies care: orphan status comes with incentives. In the UK, authorised orphan medicines normally receive 10 years of market exclusivity, which can be reduced to six if the criteria are no longer met. This financial certainty is designed to draw investment into small‑population cancers. (gov.uk)

Rules on approvals are also under review. The Secretary of State must examine how marketing authorisations for orphan cancer medicines work, look at approaches in other countries, publish conclusions within three years, and lay the report before Parliament. We’ll compare that review with the European Commission’s orphan‑medicine pathway, which uses the same prevalence threshold and a centralised process. (hansard.parliament.uk)

Where it applies matters. The new duty to facilitate research-specifically, steps to enable potential participants to be identified and contacted-applies in England and Wales. Other parts of the Act extend across the UK. That split mirrors how health services and data systems are organised. (bills.parliament.uk)

How you might hear about a study. Ministers have said, as part of the National Cancer Plan, that the NHS App will help patients see and join trials. Paired with the Act’s data‑sharing gateway, you should expect more timely invitations to consider a study-with clear information and the choice to say yes or no. (gov.uk)

If you teach or run a community group, the simple way to frame this is: the law sets a clear definition of “rare”, creates a named lead to organise research, and allows the health service to reach out to people who might benefit-while keeping UK data‑protection law in charge. It opens doors without lowering standards.

Dates to keep in mind. The Act starts on 5 May 2026. The government’s marketing‑authorisations review is due by March 2029. We’ll update you as NHS England and the Department of Health and Social Care publish practical guidance and announce the National Specialty Lead. (commonsbusiness.parliament.uk)